Global Nanomedicine Market 2017-2023: Industry Players are

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
820
Global Nanomedicine Market 2017-2023: Industry Players are Focusing Significantly on R&D to Gain Approval for Various Clinical Trials

Dublin, March 16, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Nanomedicine Market - Drivers, Opportunities, Trends, and Forecasts: 2017-2023" report to their offering. The Nanomedicine Market to Grow at a CAGR of 17.1% During the Forecast Period 2017-2023 to Aggregate $392.80 Billion By 2023

The nanomedicine market is analyzed based on two segments - therapeutic applications and regions.

The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas.

Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.

Key Topics Covered:

1 Industry Outlook 1.1 Industry Overview 1.2 Industry Trends 1.3 PEST Analysis 2 Report Outline 2.1 Report Scope 2.2 Report Summary 2.3 Research Methodology 2.4 Report Assumptions 3 Market Snapshot 3.1 Total Addressable Market (TAM) 3.2 Segmented Addressable Market (SAM) 3.3 Related Markets 3.3.1 mHealth Market 3.3.2 Healthcare Analytics Market 4 Market Outlook 4.1 Overview 4.2 Regulatory Bodies and Standards 4.3 Government Spending and Initiatives 4.4 Porter 5 (Five) Forces 5 Market Characteristics 5.1 Evolution 5.2 Ecosystem 5.2.1 Regulatory Process 5.2.2 Clinical Trials 5.2.3 Pricing and Reimbursement 5.3 Market Segmentation 5.4 Market Dynamics 5.4.1 Drivers 5.4.1.1 Emergence of nanorobotics 5.4.1.2 Applications and advantages of nanomedicine in various healthcare segments 5.4.1.3 Reasonable investments in R&D 5.4.1.4 Increased support from governments 5.4.2 Restraints 5.4.2.1 Long approval process and stringent regulations 5.4.2.2 Problems regarding nanoscale manufacturing 5.4.2.3 Risks related to nanomedicines 5.4.2.4 Undefined regulatory standards 5.4.3 Opportunities 5.4.3.1 Aging population with chronic care needs 5.4.3.2 Population and income growth in emerging countries 5.4.4 DRO - Impact Analysis 6 Trends, Roadmap and Projects 6.1 Market Trends and Impact 6.2 Technology Roadmap 7 Types: Market Size and Analysis 7.1 Overview 7.2 Global Nanomedicine Market in Oncology Segment 7.3 Global Nanomedicine Market in Cardiovascular Segment 7.4 Global Nanomedicine Market in Neurology Segment 7.5 Global Nanomedicine Market in Anti-inflammatory Segment 7.6 Global Nanomedicine Market in Anti-infective Segment 7.7 Global Nanomedicine Market in Other Therapeutic Areas 8 Trending Nanomedicines 8.1 Overview 8.2 Abraxane 8.3 Alimta 8.4 Eligard 8.5 Copaxone 8.6 Rapamune 8.7 Neulasta 8.8 Cimzia 8.9 AmBisome 8.10 Mircera 8.11 Pegasys 8.12 Emend 8.13 Renagel 8.14 Ritalin 9 Regions: Market Size and Analysis 9.1 Overview 9.1.1 Global Nanomedicine Market by Geographical Segmentation 9.2 Key Leading Countries 9.2.1 US 9.2.2 Germany 9.2.3 Japan 10 Vendor Scenario 11 Vendor Profiles 11.1 Merck & Co. Inc. 11.2 Hoffmann-La Roche Ltd. 11.3 Gilead Sciences 11.4 Novartis AG 11.5 Amgen Inc. 12 Global Generalist 12.1 Pfizer Inc. 12.2 Eli Lilly and Company 12.3 Sanofi 13 Companies to Watch for 13.1 Nanobiotix SA 13.2 UCB SA 14 Market Landscape For more information about this report visit http://www.researchandmarkets.com/research/32hqk4/global

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Nanotechnology, Nanomedicine

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

Updated Category News Views 30

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Nonprofit and Partners Gift Homes to Veterans

Updated Category News Views 87

A Heartfelt Gesture on Veterans Day Now this is the kind of story that gets you right in the gut. On November 9, two veterans, who were likely walking into a golf club thinking it was just another evening, were handed the keys to a future they might have only dreamt of: a mortgage-free home. Operation Finally Home, backed by the big names like Lennar and the patriotic...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 72

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Emergency Strobe Light Device Eyes Market Potential

Updated Category News Views 56

An Idea Sparked in San Marcos This ain't your typical cocktail party chat. We're diving into a story born from necessity—where someone's trying to shave seconds off a life-or-death situation. From the busy streets of San Marcos, California, an inventor has brought a practical gem to the table: the LIFE STROBE. This gizmo is not just a bulb with a new flash pattern. It's...

Continue Reading
Wiz Khalifa Ignites MJBizCon 2026 with Keynote and Music

Updated Category News Views 184

An Icon in Cannabis Culture Hits the Stage When you mix business with pleasure, you get something like what MJBizCon's cooking up this year. Wiz Khalifa, the man with a knack for turning passion into profit, is jumping onto the stage—not just as a performer, but also as a keynote speaker. On December 2, attendees are in for a treat as he steps into a new spotlight at...

Continue Reading
Accuray Finishes Key Deal, Resetting Financial Trajectory

Updated Category News Views 136

Accuray Secures the Deal, But Is the Future Bright? Every now and then in the investing world, a company pulls off a maneuver that you wish you’d thought of first. Today, folks, it's Accuray's turn. They've just wrapped up a monstrous transaction with TCW – their primary lender and shareholder – that has them feeling optimistic about the road ahead. Bold Moves to...

Continue Reading
Agiloft Navigates New Growth Phase with Key Leadership

Updated Category News Views 250

Leadership Shifts Steer Agiloft's EMEA Journey Agiloft's latest shake-ups in leadership signal a determined charge through EMEA's bustling markets. Nick Bowles, a seasoned veteran in enterprise software, steps into the limelight as Senior Vice President, while Jim Leason shifts gears into a customer-focused advisory role. These aren’t just routine hiring...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 85

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Samuel Oschin Center Opens, Promising Wonder

Updated Category News Views 179

A Grand New Space for Space Well, here's a sight for sore eyes—California Science Center's Samuel Oschin Air and Space Center just swung its doors open wide, and boy, it's a beast of a place. Housing a spectacle like the Space Shuttle Endeavour in a vertical launch position, it's as if they've reached up and snagged a piece of the sky itself for their exhibits. They're...

Continue Reading
Health Net Invests $3 Million in Stockton Housing

Updated Category News Views 145

Putting a Roof Over Stockton's Head The talk of the town in Stockton is Health Net stepping up with a $3 million investment. This isn't just dropping loose change in a jar; it's about tackling a mammoth issue—making affordable housing more than just a pipe dream for 75 families. Community-driven, they say. What a cozy way to paint a picture of bridging that brutal gap...

Continue Reading

Top 5 Most Recently Viewed Articles

THINK Surgical and Maxx Orthopedics Innovate Knee Surgery

Updated Category News Views 426

THINK Surgical and Maxx Orthopedics Innovate Knee Surgery THINK Surgical, a leader in orthopedic surgical robotics, recently made headlines with the groundbreaking use of Maxx Orthopedics' Freedom Total Knee implant in conjunction with their TMINI Miniature Robotic System. This significant development signals a new era in orthopedic surgery where precision and efficiency...

Continue Reading
Starboard Value's Bold Moves to Revitalize Pfizer's Future

Updated Category News Views 106

Starboard Value dropped a hefty $1 billion on Pfizer back in 2024, looking to shake things up for a company that’s been limping since its pandemic highs. This activist investor ain't just throwing money around; they’re targeting a major turnaround at a firm that's seen better days. Remember when Pfizer raked in about $100 billion off that Covid-19 vaccine? Those glory...

Continue Reading
How Aon Has Thrived: A 10-Year Investment Journey

Updated Category News Views 137

A Decade of Growth for Aon Aon has shown remarkable performance over the last ten years, significantly surpassing overall market growth with an impressive annualized return of 15.51%. As of now, Aon's market capitalization stands strong at $80.39 billion, reflecting its solid position in the industry. The Power of a $1000 Investment If an investor had taken the leap and...

Continue Reading
Worksport's Significant Growth Marks Record Sales Performance

Updated Category News Views 134

Record Sales Milestone for Worksport Net Sales Soar to Approximately $1.22 Million in August Management Highlights Commitment to Expanding Operations for Positive Cash Flow. Worksport Ltd. (NASDAQ: WKSP) is excited to share that August marked a phenomenal month for their sales efforts. Net sales reached an impressive $1,213,604.28, pushing the company's annual recurring...

Continue Reading
Major Shareholding Update from Serabi Gold plc

Updated Category News Views 235

Understanding Shareholder Notifications Recently, Serabi Gold plc made a significant announcement regarding its shareholding, detailing essential changes in the company's voting rights. This update is crucial for both current shareholders and potential investors because it helps clarify how ownership changes might affect their interests. Notifications like this are...

Continue Reading